PT  - JOURNAL ARTICLE
AU  - Navarro, Cristian Eduardo
AU  - Cárdenas-Robledo, Simón
AU  - Macea, Jaiver
AU  - Ortíz-Cano, Natalia A
AU  - Florez, Ivan D
TI  - Anti-CD20 antibodies in relapsing multiple sclerosis: Protocol for a systematic review and network meta-analysis
AID  - 10.1101/2024.01.12.24301256
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.01.12.24301256
4099  - http://medrxiv.org/content/early/2024/01/15/2024.01.12.24301256.short
4100  - http://medrxiv.org/content/early/2024/01/15/2024.01.12.24301256.full
AB  - Background Multiple sclerosis is a chronic disease of the central nervous system characterized by autoimmune demyelination. Various immunomodulatory medications are available for its treatment, among which anti-CD20 monoclonal antibodies have demonstrated superior efficacy compared to other disease-modifying therapies. However, there is a lack of direct comparison between the four available anti-CD20 monoclonal antibodies. Therefore, this study aims to systematically assess the relative efficacy and safety of anti-CD20 monoclonal antibodies for treating relapsing multiple sclerosis.Materials and Methods We will conduct a systematic review of phase IIb and phase III clinical trials of anti-CD20 monoclonal antibodies for the treatment of relapsing multiple sclerosis, following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. A comprehensive review of the Cochrane Central Register of Controlled Trials; MEDLINE; Embase; ClinicalTrials; International Clinical Trials Registry Platform; OpenGray; and MedRxiv will be performed. Two independent reviewers will select titles, abstracts, and eligible full texts to execute the data extraction. The risk of bias will be assessed with the Cochrane RoB 2 tool. Data on pre-specified outcomes will be analyzed for the selected articles using a random-effects network meta-analysis with a frequentist framework. Summary statistics, along with 95% confidence intervals will be presented, and the effectiveness and safety of each intervention will be ranked using the surface under the cumulative ranking curve. A missing data and a sensitivity analysis will be conducted. We will use the GRADE approach to assess the certainty of the direct, indirect, and network estimate for all outcomes.Results and Conclusion The results will provide evidence of the relative efficacy and safety of anti-CD20 monoclonal antibodies for the treatment of relapsing multiple sclerosis.Systematic review registration PROSPERO registration number CRD42023437996Competing Interest StatementI have read the journal's policy and the authors of this manuscript have the following competing interests: [Cristian Eduardo Navarro has declared that no competing interests exist Simón Córdenas-Robledo was a 2019-2020 ECTRIMS clinical fellow in the past three years he has received travel expenses for scientific meetings from Merck and Genzyme compensation for consulting services or participation on advisory boards from Merck, Biogen-Idec, Sanofi and Novartis lecture fees from Novartis, Merck, Sanofi, Janssen and Biogen-Idec and research support from Biogen-Idec Jaiver Macea has declared that no competing interests exist Natalia A Ortíz-Cano has declared that no competing interests exist Ivan D Florez has declared that no competing interests exist]Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=437996 Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Previous approval is not required for systematic review and meta-analysis at our institutionI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDeidentified research data will be made publicly available when the study is completed and published